GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Genmab AS (CHIX:GMABc) » Definitions » Other Current Payables

Genmab AS (CHIX:GMABC) Other Current Payables : kr3,498 Mil (As of Mar. 2025)


View and export this data going back to 2008. Start your Free Trial

What is Genmab AS Other Current Payables?

Genmab AS's Other Current Payables for the quarter that ended in Mar. 2025 was kr3,498 Mil.

Genmab AS's quarterly Other Current Payables increased from Sep. 2024 (kr3,202 Mil) to Dec. 2024 (kr3,460 Mil) and increased from Dec. 2024 (kr3,460 Mil) to Mar. 2025 (kr3,498 Mil).

Genmab AS's annual Other Current Payables increased from Dec. 2022 (kr1,735 Mil) to Dec. 2023 (kr2,341 Mil) and increased from Dec. 2023 (kr2,341 Mil) to Dec. 2024 (kr3,460 Mil).


Genmab AS Other Current Payables Historical Data

The historical data trend for Genmab AS's Other Current Payables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Genmab AS Other Current Payables Chart

Genmab AS Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Other Current Payables
Get a 7-Day Free Trial Premium Member Only Premium Member Only 915.77 1,482.76 1,734.52 2,341.09 3,459.90

Genmab AS Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Other Current Payables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2,492.67 3,384.14 3,201.85 3,459.90 3,497.95

Genmab AS Other Current Payables Calculation

Other Current Payables is the payables owed and expected to be paid within one year or one operating cycle that not otherwise classified. It includes dividends payable and all other current payables.


Genmab AS Other Current Payables Related Terms

Thank you for viewing the detailed overview of Genmab AS's Other Current Payables provided by GuruFocus.com. Please click on the following links to see related term pages.


Genmab AS Business Description

Address
Carl Jacobsens Vej 30, Valby, DNK, 2500
Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.

Genmab AS Headlines

No Headlines